Bafetinib is primarily utilized in the field of oncology, particularly for the treatment of certain types of leukemia. It functions as a potent inhibitor of Bcr-Abl tyrosine kinase, which is implicated in the pathogenesis of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). By targeting this kinase, bafetinib helps to impede the proliferation of leukemic cells, thereby offering a therapeutic option for patients who may have developed resistance to other tyrosine kinase inhibitors. Additionally, its ability to cross the blood-brain barrier makes it a potential candidate for addressing central nervous system involvement in these malignancies. Ongoing research continues to explore its efficacy and potential applications in other cancer types.